Maximus (MMS) Q3 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $1.28 billion, in line with expectations; full-year revenue guidance reiterated at $5.2 billion to $5.35 billion.

Adjusted EBITDA Margin: 15.0%, up from 14.7% year-over-year.

Adjusted EPS: $2.22, compared to $2.16 in the prior year.

Cash Flow: Operating cash flow outflow of $125 million; free cash flow outflow of $137 million.

Debt: Total debt increased to $1.65 billion from $1.55 billion; net leverage ratio at 2.0x.

Share Repurchases: Approximately 0.75 million shares repurchased for $50 million; $400 million authorization remaining.

2Strategic Updates and Business Highlights

U.S. Federal Services: Revenue of $721 million; operating income margin improved to 18.6%. Revenue decline attributed to lower natural disaster support and clinical volume surges.

U.S. Services: Revenue of $418 million; expected mid-single-digit organic growth in Q4 driven by Medicaid engagements.

Outside the U.S.: Revenue of $140 million; operating profit of $1.2 million.

Technology Investments: Continued focus on efficiency-enhancing technology and AI adoption across contracts, with 75-80% of new bids including AI requirements.

Contract Modifications: A temporary pause in performance incentives for the VA Medical Disability Exam program, impacting profitability.

3Forward Guidance and Outlook

Adjusted EPS Guidance: Revised to $7.90 - $8.20, with a midpoint of $8.05, reflecting a $0.35 reduction due to the VA contract modification.

Adjusted EBITDA Margin Guidance: Approximately 13.7% for FY 2026.

Free Cash Flow Guidance: Expected to range between $425 million and $475 million.

Q4 Expectations: Anticipated adjusted diluted EPS at midpoint of $1.91 and adjusted EBITDA margin of approximately 13.7%.

4Bad News, Challenges, or Points of Concern

VA Contract Modification: The pause in performance incentives is expected to impact profitability starting Q4 and may extend into FY 2027.

Cash Flow Concerns: Elevated Days Sales Outstanding (DSO) at 98 days due to administrative delays at a major federal customer, although collections have accelerated recently.

Market Dynamics: Procurement delays and evolving priorities in the federal market may slow the pace of contract awards and growth opportunities.

5Notable Q&A Insights

VA Incentives: Management clarified that the pause is temporary and linked to the VA's need to improve its review process. The current contract is expected to last until December 31, 2026.

Future Earnings Power: Q4 run rate is seen as a reasonable estimate for FY 2027, assuming the incentive pause continues beyond 180 days.

SNAP and Medicaid Opportunities: Management remains optimistic about growth in these areas, despite legislative complexities and the need for states to implement new requirements.

M&A Focus: The company is considering M&A as a tool for long-term growth, emphasizing the importance of high-probability revenue synergies in potential acquisitions. Overall, while Maximus reported solid Q3 results, challenges related to contract modifications and cash flow management present headwinds as they look forward to FY 2027.